Major pharmaceutical companies are redirecting capital expenditures toward domestic biomanufacturing hubs. The shift aims to lessen reliance on concentrated international active pharmaceutical ingredient (API) supply nodes following recent shipping channel disruptions.
Continuous Manufacturing Efficiency
By adopting continuous-flow processing rather than batch manufacturing, operators reduce facility footprints by up to 70% while improving real-time quality control. Regulatory bodies are expediting validation processes for domestic plants that implement automated compliance tracking.